Patents Assigned to FIBROCELL TECHNOLOGIES, INC.
-
Patent number: 10900020Abstract: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.Type: GrantFiled: January 12, 2018Date of Patent: January 26, 2021Assignee: Fibrocell Technologies, Inc.Inventors: John Maslowski, Myrna F. Thomas, Marie A. Lindner
-
Patent number: 10881695Abstract: An autologous cell therapy product composed of fibroblasts grown for each individual to be treated for vocal cord scarring. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in cryovials containing cryopreserved autologous fibroblasts or precursors thereof, at a concentration of between 1.0×107 cells/mL and 2.7×107 cells/mL, wherein at least 85% of the human fibroblast cells are viable after freezing and thawing.Type: GrantFiled: September 7, 2018Date of Patent: January 5, 2021Assignee: Fibrocell Technologies, Inc.Inventor: John Maslowski
-
Patent number: 10098914Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucsoa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells/mL.Type: GrantFiled: August 12, 2016Date of Patent: October 16, 2018Assignee: Fibrocell Technologies, Inc.Inventor: John Maslowski
-
Patent number: 9902937Abstract: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.Type: GrantFiled: May 19, 2014Date of Patent: February 27, 2018Assignee: Fibrocell Technologies, Inc.Inventors: John Maslowski, Myrna F. Thomas, Marie A. Lindner
-
Patent number: 9415075Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three tunes approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells/mL.Type: GrantFiled: June 3, 2014Date of Patent: August 16, 2016Assignee: Fibrocell Technologies, Inc.Inventor: John Maslowski
-
Publication number: 20140348801Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three tunes approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells/mL.Type: ApplicationFiled: June 3, 2014Publication date: November 27, 2014Applicant: Fibrocell Technologies, Inc.Inventor: John Maslowski
-
Publication number: 20140335057Abstract: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is needed directly into a large tissue culture flask, and passaged so more than three times.Type: ApplicationFiled: May 19, 2014Publication date: November 13, 2014Applicant: FIBROCELL TECHNOLOGIES, INC.Inventors: John Maslowski, Myrna F. Thomas, Marie A. Lindner
-
Patent number: 8765121Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells/mL.Type: GrantFiled: October 14, 2011Date of Patent: July 1, 2014Assignee: Fibrocell Technologies, Inc.Inventor: John Maslowski
-
Patent number: 8728819Abstract: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.Type: GrantFiled: August 29, 2007Date of Patent: May 20, 2014Assignee: Fibrocell Technologies, Inc.Inventors: John Maslowski, Myrna F. Thomas, Marie A. Lindner
-
Publication number: 20140099383Abstract: An autologous topical formulation containing conditioned medium obtained from culture of autologous fibroblasts has been developed. Unlike other topical formulations, it is autologous since it is derived solely from cells obtained by the person who is to use the formulation. This avoids any possible reaction with proteins derived from the cells. Preferred formulations include gels, creams, lotions, and ointments. The topical formulations of conditioned medium obtained by culturing autologous dermal fibroblasts are topically administered to individuals for the prevention and treatment of scarring, reduction in signs of aging, and improvement in quality of skin.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Fibrocell Technologies, Inc.Inventors: John M. Maslowski, Declan Daly
-
Publication number: 20140072611Abstract: Compositions for delaying, attenuating or preventing cardiac remodeling following cardiac injury contain fibroblast cells in a dosage providing an effective amount to delay, attenuate or prevent cardiac remodeling following cardiac injury. These cells are obtained by biopsy, preferably from the patient, then cultured and proliferated prior to use. It has been discovered that certain subpopulations of these cells are even better suited for repair or regeneration of tissue, the cells exhibiting properties similar to stem cells or multipotent cells. In a preferred embodiment, the cells are administered to delay, attenuate or prevent cardiac remodeling following cardiac injury.Type: ApplicationFiled: September 9, 2013Publication date: March 13, 2014Applicant: FIBROCELL TECHNOLOGIES, INC.Inventor: John M. Maslowski
-
Publication number: 20130236427Abstract: Personalized skin-specific topical formulations containing conditioned medium obtained from cultures of fibroblasts has been developed. Unlike other topical formulations, these formulations are specific for the recipient-skin type specific, and conditioned medium is obtained from a subject with desired skin characteristics. For example, since African American skin is known to wrinkle less and later than Caucasian skin, conditioned medium may be obtained from African American skin for application to pale skin. In another embodiment, the fibroblasts are obtained from young skin for administration to older skin. In still another embodiment, the fibroblasts are obtained from skin that does not suffer from acne or discoloration, for application to skin that is prone to acne or discoloration. Examples of skin donor selection criteria include delayed wrinkling, small pores, resistance to sunburn, resistance to acne, uniform coloration or lack of blotching or age spots and good moisture retention.Type: ApplicationFiled: March 5, 2013Publication date: September 12, 2013Applicant: FIBROCELL TECHNOLOGIES, INC.Inventor: David M. Pernock
-
Patent number: 8529883Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×107 cells/mL. When injected into the nasolabial fold wrinkles (creases on the sides of the nose that extend to the corners of the mouth), the autologous fibroblasts are thought to increase the synthesis of extracellular matrix components, including collagen, reducing the severity of these wrinkles. Dosage and timing of administration have been demonstrated to be critical to achieving clinically significant outcomes.Type: GrantFiled: May 7, 2010Date of Patent: September 10, 2013Assignee: Fibrocell Technologies, Inc.Inventor: John M. Maslowski
-
Publication number: 20130224160Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells/mL.Type: ApplicationFiled: October 14, 2011Publication date: August 29, 2013Applicant: FIBROCELL TECHNOLOGIES, INC.Inventor: John Maslowski